Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Integrated Investment Consultants LLC

Integrated Investment Consultants LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 71.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,697 shares of the medical research company’s stock after purchasing an additional 1,958 shares during the quarter. Integrated Investment Consultants LLC’s holdings in Amgen were worth $1,463,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Capital World Investors boosted its holdings in shares of Amgen by 1,292.0% during the fourth quarter. Capital World Investors now owns 6,495,710 shares of the medical research company’s stock valued at $1,693,042,000 after acquiring an additional 6,029,058 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Amgen by 43,573.5% during the first quarter. GAMMA Investing LLC now owns 3,661,589 shares of the medical research company’s stock valued at $1,140,768,000 after acquiring an additional 3,653,205 shares during the period. Capital International Investors boosted its holdings in shares of Amgen by 40.1% during the fourth quarter. Capital International Investors now owns 12,212,065 shares of the medical research company’s stock valued at $3,182,843,000 after acquiring an additional 3,495,503 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Amgen by 52.7% during the fourth quarter. Franklin Resources Inc. now owns 3,291,975 shares of the medical research company’s stock valued at $858,020,000 after acquiring an additional 1,135,884 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Amgen by 15.8% during the fourth quarter. Northern Trust Corp now owns 6,431,029 shares of the medical research company’s stock valued at $1,676,183,000 after acquiring an additional 875,254 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on AMGN. Erste Group Bank downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Morgan Stanley reissued an “equal weight” rating on shares of Amgen in a report on Friday, May 2nd. UBS Group boosted their price target on shares of Amgen from $315.00 to $326.00 and gave the company a “neutral” rating in a report on Monday, July 21st. Mizuho lifted their price objective on shares of Amgen from $235.00 to $280.00 and gave the company a “neutral” rating in a research note on Wednesday, May 7th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $305.00 price objective on shares of Amgen in a research note on Tuesday, June 24th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $307.27.

Insiders Place Their Bets

In related news, SVP Rachna Khosla sold 1,500 shares of Amgen stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president owned 8,162 shares of the company’s stock, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.76% of the company’s stock.

Amgen Price Performance

Shares of Amgen stock opened at $306.58 on Friday. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. The company’s 50-day moving average price is $289.39 and its two-hundred day moving average price is $290.70. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $340.89. The stock has a market cap of $164.85 billion, a PE ratio of 27.97, a price-to-earnings-growth ratio of 2.67 and a beta of 0.49.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, topping analysts’ consensus estimates of $4.18 by $0.72. The firm had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. Amgen’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $3.96 EPS. As a group, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.